Complete testing solution optimizes time and money spent on
programs to save more lives
HALIFAX,
March 18, 2014 /CNW/ - MedMira
Inc. (TSXV: MIR) will submit a new application for its
most advanced Reveal Rapid HIV Antibody Test (Reveal HIV) to the
WHO Prequalification of Diagnostics Programme. The latest
version of Reveal HIV, recently approved in the European Union,
delivers faster and more convenient point-of-care testing in the
field through its simplified test procedure and the direct use of
whole blood specimens. These new features are also in the
Reveal and Multiplo products currently being commercialized in
preparation for FDA submission.
The MedMira management team made the decision to
submit its most advanced Reveal HIV test to the WHO for
prequalification based on the company's commitment to offer
state-of-the-art technology and testing solutions to every corner
of the world. Prequalification of the latest Reveal HIV format will
also enable MedMira's global strategic partners to bring the best
technology and products to all markets where care providers and
patients can benefit from faster, more cost-effective testing
solutions. As MedMira rolls out this advanced version of Reveal HIV
around the globe, legacy products will be phased out and the
company will no longer support previous versions of the test,
including the format originally submitted to the WHO for
prequalification.
"Healthcare providers around the world are
demanding the most advanced technology that qualified rapid test
developers have to offer in order to meet the increasing need for
screening tools that help prevent and control the spread of deadly
diseases like HIV. By submitting Reveal HIV, built on the
latest advances in our Rapid Vertical Flow Technology, for
prequalification, MedMira is answering the WHO's call for
state-of-the art, innovative products needed in their programs,"
said Hermes Chan, CEO, MedMira
Inc.
Chan added, "Cost efficiency combined with high
quality tests are critical to all government and non-government
organizations running testing programs. MedMira is creating
new modelling tools to help care providers optimize their program
outputs and maximize available budgets, especially important in
regions where large scale screening programs have the most
impact. Our goal is to provide a comprehensive testing
solution that includes the most advanced diagnostic technology, the
highest quality tests, and optimization tools to save lives."
About MedMira
MedMira is a leading developer and manufacturer
of vertical flow rapid diagnostics. The Company's tests provide
hospitals, labs, clinics and individuals with instant diagnosis for
diseases such as HIV and hepatitis C in just three easy steps. The
Company's tests are sold under the Reveal®, Multiplo™ and Miriad™
brands in global markets. Based on its patented Rapid Vertical Flow
Technology™, MedMira's rapid HIV test is the only one in the world
to achieve regulatory approvals in Canada, the United
States, China and the
European Union. MedMira's corporate offices and manufacturing
facilities are located in Halifax, Nova
Scotia, Canada. For more information visit medmira.com.
This news release contains forward-looking
statements, which involve risk and uncertainties and reflect the
Company's current expectation regarding future events including
statements regarding possible approval and launch of new products,
future growth, and new business opportunities. Actual events
could materially differ from those projected herein and depend on a
number of factors including, but not limited to, changing market
conditions, successful and timely completion of clinical studies,
uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from
time to time in the company quarterly filings.
Neither TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
SOURCE MedMira Inc.
